Cingulate Q2 10-Q: $28.4M Cash, Going Concern Doubt, FDA CRL Details
CING sits 62% above its 52-week low of $3.16 on light trading volume (0.2× avg).
Summary
Cingulate's Q2 10-Q details a going concern warning, FDA manufacturing deficiencies for its lead drug, and ongoing dilutive financing, despite $28.4 million in cash.
Key Events · Earnings and Guidance · CING
-
Going Concern Doubt
Management states substantial doubt about the company's ability to continue as a going concern within one year after the financial statement issuance date.
-
FDA Complete Response Letter
The CRL for CTx-1301 identified specific Chemistry, Manufacturing and Controls (CMC) information requests; no clinical safety or efficacy concerns were raised.
-
CDMO Form 483
The FDA issued a Form 483 with three observations to the CDMO's facility in February 2026; two facility-related and one specific to CTx-1301.
-
Cash Runway
Cash and cash equivalents of $28.4 million as of June 30, 2026, expected to fund operations into mid-2027.
Analysis · CING · Life Sciences
Cingulate's 10-Q confirms the Q2 results but adds critical detail: the company has substantial doubt about its ability to continue as a going concern within one year. The filing also reveals the FDA's Complete Response Letter for CTx-1301 cited manufacturing deficiencies, and the CDMO received a Form 483 with three observations. While $28.4 million in cash provides runway into mid-2027, the company continues to raise capital through multiple dilutive mechanisms, including a $100 million ATM and a $25 million equity line with Lincoln Park. The going concern language and regulatory setbacks are the key risks for investors.
At the time of this filing, CING was trading at $5.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.2M. The 52-week trading range was $3.16 to $11.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.